Clinical value of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermia in advanced ovarian cancer / 中国基层医药

ABSTRACT

Objective To evaluate the efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermia in the treatment of advanced ovarian cancer .Methods From June 2014 to April 2017,72 patients with advanced ovarian cancer who were treated in the Maternal and Child Health Care Hospital of Weihai were selected as the research subjects.According to the digital table method ,the patients were randomly divided into two groups,with 36 cases in each group.The control group was treated with neoadjuvant chemotherapy combined with cytoreductive surgery.The observation group was treated with neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermic perfusion.After 3 months of chemotherapy ,the curative effect was statistically analyzed.Results The operation time,the amount of ascites and the amount of bleeding in the observation group were significantly less than those in the control group ( all P＜0.05).There were no statistically significant differences in surgical incision stage I healing rate and the rate of pelvic infection between the two groups (P＞0.05).After treatment,the remission rate in the control group was 55.5%(20／36),which was significantly lower than 77.8%(28／36) in the observation group (χ2 ＝4.92,P＜0.05).All patients were followed up for 1 year.The recurrence rate of the control group was 33.3%,which was significantly higher than 22.2%of the observation group (χ2 ＝5.71, P ＜0.05 ).Conclusion Neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermia in the treatment of advanced ovarian cancer is effective and worthy of clinical application .